Hidehito HORINOUCHI· @HHorinouchi · X·· 1 day agoScore70
Body · original
🔥Krascendo 1: Divarasib vs sotorasib/adagrasib in previously treated KRAS G12C-mutated NSCLC
🆙 @NEJM #ESMO26
☑Phase 3 RCT; N=338; mFU 14.3 mo
🎯mPFS 9.8 vs 5.7 mo (HR 0.58, p<0.001); mOS 17.7 vs 12.0 mo (HR 0.56, p<0.001); ORR 58.4 vs 32.3%
🎙 @FSkoulidis
#LCSM @OncoAlert @Larvol @KRASKickers
https://www.nejm.org/doi/full/10.1056/NEJMoa2605703
142 views · 4 likes · 3 reposts · 0 replies
Conference abstracts
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org🆙#ESMO26 Presidential Symposium II: #LCSM 🔥Krascendo 1: Efficacy and Safety of Divarasib (Diva) vs Sotorasib (Soto) or Adagrasib (Ada) in Previously Treated Locally Advanced or Metastatic KRAS G12C-Mutated NSCLC 🎙️ @FSkoulidis 🔢LBA5 🎯Significantly Improved PFS (9.8 vs 5.7mo, HR 0.58; n=338) and OS (17.7 vs 12.0mo, HR 0.56, p=0.0005) 🎯ORR 58.4% vs 32.3% 🎯Discontinuation Due to TRAEs 4.8% vs 11.7% ☑️NCT06497556 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348 @OncoAlert @Larvol @myESMO @IASLC @KRASKickers在 X 查看被引用的帖子
Source: Hidehito HORINOUCHI · x.com